Stock Financial Ratios, Dividends, Split History

PBPB / Potbelly Corp financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)335.89
Enterprise Value ($M)307.51
Book Value ($M)116.78
Book Value / Share4.59
Price / Book2.59
NCAV ($M)-4.74
NCAV / Share-0.19
Price / NCAV-70.64
Share Statistics
Common Shares Outstanding 25,107,188
Weighted Average Number Of Diluted Shares Outstanding 25,045,427
Weighted Average Number Of Shares Outstanding Basic 25,045,427
Common Stock Shares Outstanding 24,999,688
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.06
Return on Assets (ROA)-0.04
Return on Equity (ROE)-0.05
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.86
Income Statement (mra) ($M)
Franchise Revenue2,500,000.00
Sales Revenue Goods Net424,932,000.00
Revenue From Franchise Royalties And Fees3,179,000.00
Operating Income-1.92
Net Income-6.69
Earnings Per Share Diluted-0.28
Earnings Per Share Basic-0.28
Cash Flow Statement (mra) ($M)
Cash From Operations41.82
Cash from Investing-34.68
Cash from Financing41.82
Identifiers and Descriptors
Central Index Key (CIK)1195734
Related CUSIPS
73754Y900 73754Y950

Split History

Stock splits are used by Potbelly Corp to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Streamlining Won’t Boost McDonald’s Corporation Long Term

2018-06-11 investorplace
McDonald’s Corporation (NYSE:MCD) has begun to focus on a turnaround. The world’s second-largest fast-food chain has seen store traffic drop amid changing food trends. Now, the company plans to lay off workers and put in a new field structure to better support franchises. However, the price of MCD stock has not reflected these and other struggles. Given increasing valuations and falling revenues, investors should avoid McDonald’s stock. (46-0)

Roast-Beef King Arby’s Is Betting Big on Lamb - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (3-0)

Potbelly (PBPB) Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Welcome to the Potbelly Corporation First Quarter 2018 Earnings Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded. (1-0)

U.S. Retailers Saw Strong Holiday Results Roll Into Q1

2018-05-08 seekingalpha
In the U.S. retail landscape, the strength seen this past holiday season continued into the first quarter of 2018. In fact, analysts polled by Thomson Reuters are becoming more bullish on consumer spending as retailers get ready to report their earnings for Q1 2018. (159-0)

CUSIP: 73754Y100